Search Results - "Cantrell, Matthew A"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    Alvimopan for postoperative ileus by Bream-Rouwenhorst, Heather R, Cantrell, Matthew A

    Published in American journal of health-system pharmacy (15-07-2009)
    “…The efficacy, safety, pharmacology, pharmacokinetics, drug-drug interactions, and administration of alvimopan for postoperative ileus are reviewed. Alvimopan…”
    Get full text
    Journal Article
  2. 2

    Lack of Association Between 5α-Reductase Inhibitors and Depression by Dyson, Tess E, Cantrell, Matthew A, Lund, Brian C

    Published in The Journal of urology (01-10-2020)
    “…Depressed mood and suicidality reported with 5α-reductase inhibitors (5-ARIs; finasteride and dutasteride) during post-marketing surveillance resulted in the…”
    Get full text
    Journal Article
  3. 3

    Reprint of: The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease by Opheim, Karla M., Uc, Ergun Y., Cantrell, Matthew A., Lund, Brian C.

    “…Alpha-1-adrenergic receptor antagonists (AARAs) are used in the treatment of benign prostatic hypertrophy. Some AARAs, such as terazosin, stimulate glycolysis…”
    Get full text
    Journal Article
  4. 4

    The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease by Opheim, Karla M., Uc, Ergun Y., Cantrell, Matthew A., Lund, Brian C.

    “…Alpha-1-adrenergic receptor antagonists (AARAs) are used in the treatment of benign prostatic hypertrophy. Some AARAs, such as terazosin, stimulate glycolysis…”
    Get full text
    Journal Article
  5. 5

    Glucagon-like peptide receptor agonists and risk for depression by Tagliapietra, Gabriella A., Cantrell, Matthew A., Lund, Brian C.

    Published in Primary care diabetes (01-08-2024)
    “…Package labeling for weight loss formulations of semaglutide and liraglutide include a warning for suicidal thoughts and behaviors. The objective was to…”
    Get full text
    Journal Article
  6. 6

    Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia by Cantrell, Matthew A., Baye, Jordan, Vouri, Scott Martin

    Published in Pharmacotherapy (01-06-2013)
    “…Tadalafil is a phosphodisesterase (PDE)‐5 inhibitor recently approved by the United States Food and Drug Administration for lower urinary tracts symptoms…”
    Get full text
    Journal Article
  7. 7

    Comparative Effectiveness of Anticholinergic Agents for Lower Urinary Tract Symptoms by Goodson, Ali B, Cantrell, Matthew A, Shaw, Robert F, Lund, Brian C

    “…Limited data from short-term clinical trials suggest efficacy advantages of solifenacin and fesoterodine over other anticholinergic agents in the treatment of…”
    Get full text
    Journal Article
  8. 8

    Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system by Titus-Rains, Krystal S, Cantrell, Matthew A, Egge, Jason A, Alexander, Bruce, Shaw, Robert F, Argo, Tami R

    Published in American journal of health-system pharmacy (01-12-2016)
    “…PURPOSEThe question of whether publication of selected clinical trials is temporally followed by changes in prescribing of adjunctive lipid-lowering…”
    Get full text
    Journal Article
  9. 9

    Intraoperative Floppy Iris Syndrome Associated with α1-Adrenergic Receptor Antagonists by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Steffensmeier, Andrew, Hemerson, Phyllis, Rogers, Meaghan, Stamper, Benton

    Published in The Annals of pharmacotherapy (01-04-2008)
    “…OBJECTIVE: To describe intraoperative floppy iris syndrome (IFIS) in association with α1-adrenergic receptor (α1AR) antagonists by conducting a thorough…”
    Get full text
    Journal Article
  10. 10

    Varenicline for Tobacco Dependence by Cantrell, Matthew A, Geraets, Douglas

    Published in The New England journal of medicine (12-02-2009)
    “…To the Editor: In the November 6 issue, Hays and Ebbert review the use of varenicline (Chantix) for tobacco dependence. 1 Although this review highlights the…”
    Get full text
    Journal Article
  11. 11

    Silodosin for Benign Prostatic Hyperplasia by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Hemerson, Phyllis, Magera, James S, Jr

    Published in The Annals of pharmacotherapy (01-02-2010)
    “…To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1A)-adrenergic receptor (AR) antagonist for…”
    Get full text
    Journal Article
  12. 12

    Promoting health communication between the community-dwelling well-elderly and pharmacists: The Ask Me 3 program by Miller, Michael J., Abrams, Mary Ann, Barbara, McClintock, Cantrell, Matthew A., Dossett, Corey D., McCleeary, Erin M., McGee, Meridith J., O'Keefe, Kelly J., Sager, Emily R.

    “…To describe readiness to use clear health communication principles with a pharmacist before and after participating in the Ask Me 3 (What is my main problem?,…”
    Get full text
    Journal Article
  13. 13

    The Impact of Alpha-1-Adrenergic Receptor Antagonists on the Progression of Parkinson's Disease by Opheim, Karla M, Uc, Ergun Y, Cantrell, Matthew A, Lund, Brian C

    “…Alpha-1-adrenergic receptor antagonists (AARA) are used in the treatment of benign prostatic hypertrophy. Some AARAs, such as terazosin, stimulate glycolysis…”
    Get full text
    Journal Article
  14. 14

    Preemptive dose reduction of warfarin in patients initiating metronidazole by Holt, Ryan K, Anderson, Erin A, Cantrell, Matthew A, Shaw, Robert F, Egge, Jason A

    Published in Drug metabolism and drug interactions (01-12-2010)
    “…The goal of this study was to determine if preemptive dose reduction (PDR) of warfarin is effective in maintaining therapeutic anticoagulation in patients…”
    Get more information
    Journal Article
  15. 15

    New Drug Approvals: Silodosin for Benign Prostatic Hyperplasia by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Hemerson, Phyllis, Magera, James S

    Published in The Annals of pharmacotherapy (01-02-2010)
    “…Objective: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved α1A-adrenergic receptor (AR) antagonist…”
    Get full text
    Journal Article
  16. 16

    Intraoperative Floppy Iris Syndrome Associated with α 1 -Adrenergic Receptor Antagonists by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Steffensmeier, Andrew, Hemerson, Phyllis, Rogers, Meaghan, Stamper, Benton

    Published in The Annals of pharmacotherapy (01-04-2008)
    “…OBJECTIVE: To describe intraoperative floppy iris syndrome (IFIS) in association with α 1 -adrenergic receptor (α 1 AR) antagonists by conducting a thorough…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Steffensmeier, Andrew, Hemerson, Phyllis, Rogers, Meaghan, Stamper, Benton

    Published in The Annals of pharmacotherapy (01-04-2008)
    “…To describe intraoperative floppy iris syndrome (IFIS) in association with alpha(1)-adrenergic receptor (alpha(1)AR) antagonists by conducting a thorough…”
    Get full text
    Journal Article
  19. 19